PUNE, India, March 30, 2016 /PRNewswire/ --
As per a new report, "Hepatitis C Virus Market: 2016 Edition," the demand for HCV will be driven by comfort of reimbursement, growth in the number of patients, smaller period of drug treatment, increasing healthcare expenditure and treatment of warehoused patients. Some of the noteworthy trends and developments of this industry are launch of interferon free regimen and development of new products. However, the expansion of HCV market is hindered by regulatory risks, patent risk, risk associated with drug development and increased competition.
The Global Hepatitis C Virus (HCV) Market Report: 2016 Edition research of 60 pages with 47 Charts and 12 Tables, 4 company profiles is now available in the pharmaceuticals segment of MarketReportsOnline.com at http://www.marketreportsonline.com/451810.html.
There was no proper therapy for HCV before 2010 but the coming of therapies like Sovaldi and Harvoni by Gilead and Viekira Pak by AbbVie has improved the scenario. Also the steps taken like proper blood screening is also helping in identifying the patients.
Company Coverage of Hepatitis C Virus (HCV) Market: Gilead Sciences, AbbVie, Johnson & Johnson And Bristol-Myers Squibb.
The key factors which are anticipated to drive HCV market include medical reimbursement because of the therapy being very costly, growth in the number of patients, relatively smaller period of drug treatment from before, treatment of the warehoused patients who were waiting for a better therapy and pricing discounts and better regimens because of the increased competition. Some of the significant developments of this HCV market include launch of the interferon free regimen and development of products like Sovaldi, Harvoni and Viekira Pak and the newly identified and diagnosed patients. However, the challenges to be faced ahead is more number of patients asking for reimbursement, increasing competition leading to price cutting, risk associated with drug development and regulatory risk.
Order a copy of this Global HCV Market research report at http://www.marketreportsonline.com/contacts/purchase.php?name=451810.
This report offers a comprehensive analysis of the HCV market. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. On the contention front, the global HCV market is reined by few major players namely Gilead Sciences, AbbVie, Johnson & Johnson and Bristol-Myers Squibb. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.
Many new therapies are under clinical trials for achieving more efficiency and cure rate. HCV mainly spreads through blood transfusion and poorly sterilized medical equipments resulting in liver cirrhosis and even leading to liver failure. The main reason that many patients go undiagnosed and not aware of the infection is because it affects very slowly and its symptoms take years to be recognized but today initiatives like proper blood screening has helped in recognizing more patients. Regular alcohol consumption and taking of drugs are also the reasons for getting caught by the infection. Many people use to skip the therapy till some years back because of long duration of treatment and being very costly but the market is increasing due to the coming of more effective therapies and reimbursement policies.
The Global Hepatitis C Virus (HCV) Market Report: 2016 Edition presents an in-depth analysis of the global industry along with a focus on all major regions. A thorough analysis has been conducted on key market players covering their business overview, product portfolio, financial overview and business strategies.
Explore more pharmaceuticals market research as well as other newly published reports by Koncept Analytics at http://www.marketreportsonline.com/publisher/koncept-analytics-market-research.html.
On a similar note, the Hepatitis C Virus (HCV) Protease Inhibitors -Pipeline Insights, 2016 market research report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Read more at http://www.marketreportsonline.com/440271.html .
About Us:
MarketReportsOnline.com comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets.
Contact Us:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
Tel: + 1 888 391 5441
E-mail: sales@marketreportsonline.com
